TopNews United States
Novartis' heart failure drug faces hurdles despite upbeat PhIII results
Novartis has detailed the hits and misses from a late-stage trial of its potential blockbuster therapy for acute heart failure, serelaxin, calling the study an overall success and making executives of the Swiss drug giant confident in their plans to ...
Serelaxin: Acute Heart Failure Drug Reduces Deaths By 37%, Study Shows
RELAX-AHF: Serelaxin reduces dyspnea, but questions surround mortality benefit
Pregnancy Hormone May Have Role in HF